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Abstract Patients with polycythemia vera (PV), a myelopro-
liferative neoplasm characterized by an elevated red blood cell
mass, are at high risk of vascular and thrombotic complica-
tions and have reduced quality of life due to a substantial
symptom burden that includes pruritus, fatigue, constitutional
symptoms, microvascular disturbances, and bleeding. Con-
ventional therapeutic options aim at reducing vascular and
thrombotic risk, with low-dose aspirin and phlebotomy as
first-line recommendations for patients at low risk of throm-
botic events and cytoreductive therapy (usually hydroxyurea
or interferon alpha) recommended for high-risk patients.
However, long-term effective and well-tolerated treatments
are still lacking. The discovery of mutations in Janus kinase
2 (JAK2) as the underlying molecular basis of PV has led to
the development of several targeted therapies, including JAK
inhibitors, and results from the first phase 3 clinical trial with a
JAK inhibitor in PV are now available. Here, we review the
current treatment landscape in PV, as well as therapies current-
ly in development.
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Introduction
Polycythemia vera (PV), along with primary myelofibrosis
(MF) and essential thrombocythemia (ET), is a classic Phila-
delphia chromosome-negative myeloproliferative neoplasm
(MPN) characterized primarily by an increased red blood cell
mass [1–5]. Patients with PV have excessive proliferation of
not only erythroid but also myeloid and megakaryocytic com-
ponents in the bone marrow, resulting in high red blood cell,
white blood cell (WBC), and platelet counts [2, 3, 5]. Clini-
cally, patients with PV may experience symptoms such as
pruritus, fatigue, night sweats, bone pain, thrombosis, and
bleeding [3]. Furthermore, patients with PV have a reduced
quality of life and are at risk of transformation to secondary
MF and acute myeloid leukemia (AML). Therapeutic options
are limited, and available therapies (e.g., low-dose aspirin,
phlebotomy, hydroxyurea (HU)) are mainly palliative and fo-
cus on preventing the occurrence of thrombosis and improv-
ing symptoms.
PV has a much higher prevalence than does MF (44–
57 per 100,000 persons vs 4–6 per 100,000, respectively)
[6]. In Europe, the incidence of PV ranges from 0.4 per
100,000 persons per year to 2.8 per 100,000 per year [7],
and patients with PV have a 1.6-fold higher risk of death
than the general population [8]. PV affects more men
than women, with the median age of diagnosis being
60 years [8]; however, approximately 20 to 25 % of
patients are younger than 40 years [9]. The median sur-
vival in patients with PV is 14.1 years, but it is much
lower in those older than 60 years and/or with a history
of thrombosis (8.3 years) [10].
The understanding of the pathogenesis of PV vastly
grew after activating mutations in the Janus kinase 2
(JAK2) gene were identified in most patients with PV,
with the classical JAK2 V617F mutation present in
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approximately 96 % and JAK2 exon 12 mutations in ap-
proximately 3 % of pat ients with PV [11, 12] .
Overactivation of JAK2 autonomously activates down-
stream pathways, including JAK/STAT, leading to unreg-
ulated hematopoiesis. These findings have been instru-
mental in shaping criteria for diagnosis and treatment, so
much that the presence of the JAK2 V617F mutation is a
major criterion in the diagnosis of PV [1] and JAK2 in-
hibitors are in development as targeted molecular thera-
pies for PV [3, 13].
PV diagnosis is currently based on the 2008 World
Health Organization (WHO) diagnostic criteria (Table 1)
[1]. The WHO diagnostic criteria emphasize laboratory
values, morphologic features, and genetic data, with
erythrocytosis being the first major criterion. According
to the WHO, evidence of erythrocytosis includes elevated
hemoglobin (Hgb) levels (>18.5 g/dL in men and >16.5 g/
dL in women), but other groups, such as the British Com-
mittee for Standards in Haematology and the Polycythe-
mia Vera Study Group, emphasize the use of elevated
hematocrit (Hct) value (>48 % in women and >52 % in
men) [14] or red cell mass measurement, respectively
[15–17]. Recently, some investigators have proposed re-
vising the WHO criteria [18], especially following the
identification of masked PV (mPV) in a subgroup of pa-
tients with PV [19]. Unlike patients with overt PV, pa-
tients with mPV tend to have normal or borderline Hgb
and Hct values but are usually positive for JAK2 muta-
tions, have bone marrow features consistent with PV, and
have low serum erythropoietin levels. Barbui and col-
leagues [19] stated that a revision to the current WHO
diagnostic criteria with emphasis on a lower Hgb thresh-
old and/or the use of Hct threshold values may be helpful
in accurately diagnosing those with mPV and could allow
for appropriate and prompt treatment of these patients.
Symptom burden and complications of PV
Symptomatic burden in PV is severe and present in most pa-
tients with the disease [20]. The most common complaints are
fatigue (reported by 88 % of patients), pruritus (62 %), night
sweats (52 %), bone pain (50 %), fever (18 %), and weight
loss (31 %), with pruritus and fatigue being the most prevalent
and troublesome symptoms [3, 20]. Pruritus presents as gen-
eralized burning, pricking, tingling, or itching and is frequent-
ly reported after water contact (aquagenic pruritus); large tem-
perature shifts, alcohol consumption, or exercise may induce
comparable symptoms. Symptoms may persist up to 40 min
and are often associated with aggression, irritability, depres-
sion, and suicidal ideation. Fatigue has been identified as the
consequence of circulating cytokines (tumor necrosis factor
alpha, interleukin-1, interleukin-6) [3]. Additionally, approxi-
mately 35 to 45 % of patients may develop splenomegaly,
although its presence is usually indicative of advanced disease
[10]. Splenomegaly usually results in secondary symptoms,
including abdominal pain, early satiety, weight loss, and nau-
sea, and complications can lead to abdominal organ compres-
sion and portal hypertension [3].
PV-associated constitutional symptoms and symptoms as-
sociated with splenomegaly are present in 70 % of patients
and compromise quality of life [3, 21], as assessed by tools
such as the European Organisation for Research and Treat-
ment of Cancer Quality of Life Questionnaire Core 30 and/
or the MPN-Symptom Assessment Form (SAF) question-
naires [20, 21]. An abbreviated version of the MPN-SAF,
the MPN-SAF Total Symptom Score, was recently developed
to provide an efficient tool for assessing symptom burden in
patients with MPN. The MPN-SAF Total Symptom Score is a
ten-item scoring instrument focusing on fatigue, concentra-
tion, early satiety, inactivity, night sweats, itching, bone pain,
abdominal discomfort, weight loss, and fevers [22]. Based on
Table 1 World Health
Organization criteria for
diagnosing polycythemia vera
Major criteria Minor criteria
Hgb >18.5 g/dL in men, >16.5 g/dL in women, or
other evidence of increased red cell volumea
Bone marrow biopsy showing hypercellularity for age
with trilineage growth with prominent erythroid,
granulocytic, and megakaryocytic proliferation
Presence of JAK2 V617F or other functionally
similar mutations, such as JAK2 exon 12
mutations
Serum erythropoietin level below the reference range
for normal
Endogenous erythroid colony formation in vitro
Diagnosis requires the presence of both major criteria and one minor criterion or the presence of the first major
criterion together with two minor criteria. Republished with permission of the American Society of Hematology,
from Vardiman JW et al. [1]; permission conveyed through Copyright Clearance Center, Inc.
Hct hematocrit, Hgb hemoglobin
a Hgb or Hct >99th percentile of method-specific reference range for age, sex, and altitude of residence OR Hgb
>17 g/dL in men and >15 g/dL in women if associated with a documented and sustained increase of at least 2 g/
dL from a person’s baseline value that cannot be attributed to correction of iron deficiency OR elevated red cell
mass >25 % above mean normal predicted value
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these tools, the symptom burden in patients with PV at diag-
nosis has been found to be comparable to or worse than that
observed in patients with newly diagnosed primary MF [21].
The most frequent complications of PV are vascular and
thromboembolic events and hemorrhages [5]. Thrombosis is a
prominent symptom observed in up to 39 % of patients with
PVat diagnosis [23]. The most frequent types of major throm-
bosis include stroke, transient ischemic attack, myocardial in-
farction, peripheral arterial thrombosis, deep venous thrombo-
sis, portal vein thrombosis, and thrombosis of the hepatic
veins causing Budd-Chiari syndrome [23, 24]. In addition to
macrovascular complications, patients may experience micro-
vascular symptoms (e.g., headaches, dizziness, visual distur-
bances, distal paresthesia, acrocyanosis), with erythromelalgia
being the most characteristic disturbance and consisting of
congestion, redness, and burning pain in the extremities
[24]. In cases of extreme thrombocytosis (e.g., >1500×109/
L), patients may be at risk for developing acquired von
Willebrand syndrome, which causes a bleeding diathesis
[25]. Hemorrhage is also a significant cause of morbidity
and mortality in patients with PV [25], with a cumulative
incidence of 39.6 % (6.2 % per person-year). Additionally,
overall survival has been found to be significantly shorter
among patients with hemorrhage than among those without
this complication (median overall survival, 94.8months vs not
reached; P=0.002) [25].
PValso carries a risk of transformation into acute leukemia
[5]. The incidence of transformation to AML/myelodysplastic
syndrome in patients with PV ranges from 5 to 15 % after
10 years of disease, with progressive risk over time [26]. Ad-
vanced age; female sex; and the use of alkylating drugs, radi-
ation, or a combination of cytoreductive drugs are associated
with a higher risk of leukemic transformation [26].
Current recommended therapies
Therapeutic options in PVare limited and no cure is available.
The goal of current therapies is to prevent the occurrence of
thrombosis/vascular events and delay transformation toMF or
AML [3, 12, 27, 28]. To this end, treatments for PV aim at
targeting an Hct <45 %, as this has been associated with a
reduction in cardiovascular deaths and thrombotic events
[29–31]. Poorly controlled Hct has been reported to lead to
an increased risk of thrombosis because elevated Hct can in-
crease blood viscosity, reduce blood return through the venous
system, and increase platelet adhesion [32–34]. A small retro-
spective landmark study in PV found that the incidence of
thrombotic increased linearly in men and women when Hct
was >45 % (range, 46–52 %) [35]. More recently, Marchioli
et al. tested this recommendation in the Cytoreductive Thera-
py in Polycythemia Vera (CYTO-PV) study (N=365), a large-
scale, prospective, randomized clinical trial comparing the
benefits and risks of conventional treatment aimed at main-
taining Hct <45 versus 45 to 50 % [36] and found a lower rate
of cardiovascular deaths and major thrombotic events in pa-
tients with a target Hct of <45% than in those with a target Hct
of 45 to 50 % [31]. The incidence of events was 1.1 per 100
patient-years in the low-Hct group compared with 4.4 per 100
patient-years in the high-Hct group.
Initial treatment depends on the risk stratification of the
patient, which is shaped by his or her risk of thrombosis [18,
37, 38] and is not designed to estimate survival or the risk of
leukemic/fibrotic transformation (Fig. 1) [37]. Patients can be
stratified in Bhigh-risk^ or Blow-risk^ categories according to
whether they are older or younger than 60 years and have a
history of thrombosis. Low-risk patients have zero risk fac-
tors; high-risk patients have one or two risk factors [37, 38].
An Bintermediate-risk^ category that includes younger pa-
tients with coexisting cardiovascular risk factors in the ab-
sence of previous thrombosis has been proposed but has not
been formally evaluated [24, 38]. Leukocytosis and JAK2
V617F allele burden have been identified as novel thrombotic
risk factors but have not been confirmed as such yet [10, 24,
38]. In support of leukocytosis being a risk factor, leukocyto-
sis at PV diagnosis has been associated with patients having a
higher risk of developing arterial thrombosis and acute leuke-
mia, with both of these complications resulting in a shorter
survival [26, 39]. Additionally, leukocytosis was found to be
an independent risk factor in the European Collaboration on
Low-Dose Aspirin in Polycythemia (ECLAP) study [40], and
furthermore, persistence of leukocytosis despite treatment
with HU was associated with a higher risk of hematologic
transformation and shorter survival [41]. Unlike leukocytosis,
the influence of JAK2 V617F on thrombotic risk is not clear.
Studies have shown that patients harboring a >75 % JAK2
V617F allele burden are at higher relative risk of developing
major cardiovascular and thrombotic events [42]. However, a
study by Tefferi and colleagues found no correlation between
major cardiovascular events and JAK2 V617F allele burden
[43]. Additionally, age >65 years, male sex, and leukocytosis
>10×109/L at diagnosis are all associated with a significantly
shorter survival [40, 41]. Interestingly, when the different
items included in the composite European LeukemiaNet
(ELN) response definition were individually considered, be-
ing in sustained response as related to PV-related symptoms,
spleen size by palpation, Hct, or WBC count was not associ-
ated with any significant reduction in the incidence rate of
vascular events [41].
Low-risk patients (aged<60 years and with no prior history
of thrombosis) are treated with low-dose aspirin and phlebot-
omy [3, 37]. The efficacy and safety of low-dose aspirin
(100 mg daily) were assessed in the ECLAP double-blind,
placebo-controlled, randomized clinical trial (N=518) [44].
A follow-up of 3 years showed a significant reduction in car-
diovascular death, nonfatal myocardial infarction, nonfatal
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stroke, and major venous thromboembolism; major bleeding
was not significantly increased. Low-dose aspirin can be used
alone (generally in patients with early-stage PV) or can be
used in combination with phlebotomy. Phlebotomy lowers
Hct values, thus reducing blood hyperviscosity [3], and should
be continued until Hct reaches <45 % [31]. Cytoreductive
therapy should also be considered for low-risk patients who
cannot tolerate phlebotomy, still have severe disease-related
symptoms or progressive splenomegaly, or have platelet
counts >1500×109/L or progressive leukocytosis [13]. The
addition of cytoreductive therapy is also recommended for
patients at high risk for vascular complications.
For high-risk patients, HU or interferon alpha (IFN-α) are
the first-line treatment recommendations [13, 37]; however,
IFN-α is not licensed for treatment of PV in most European
countries. HU is a cytoreductive agent that decreases the pro-
duction of all cell lines produced in the bone marrow. HU is
useful in controlling PV-related symptoms, splenomegaly,
leukocytosis, thrombocytosis, and Hct [41]. However, HU-
treated patients can eventually become resistant or experience
unacceptable adverse effects (HU intolerance), including skin
ulcers, a reduction in blood cells, gastrointestinal problems,
oral ulcers, stomatitis, hyperkeratosis, or actinic keratosis.
IFN-α has been shown to have antiproliferative effects on
hematopoietic precursor cells, induce cytogenetic remissions,
and reduce JAK2 V617F allele burden in patients with MPNs
[13]. Unfortunately, intolerable adverse effects, including flu-
like symptoms, fatigue, and neuropsychiatric symptoms, and
autoimmune problems, such as thyroiditis, have limited its use
in PV [13, 24]. Furthermore, prolonged evaluation of IFN-α
has been quite difficult because approximately 25 to 40 % of
patients with PV treated with IFN in clinical trials
discontinued treatment within 1 to 2 years due to adverse
effects [45, 46]. Other second-line cytoreductive therapy
choices for patients who experience resistance or intolerance
to HU include busulfan, pipobroman, or 32P [13]. These
agents , however, have been l inked to poten t ia l
leukemogenicity [47] and are usually reserved for elderly pa-
tients (aged ≥70–80 years) or those with advanced disease, in
whom the risk of thrombosis outweighs the risk of AML/
myelodysplastic syndromes.
Unmet medical needs with current strategies
Although some patients respond well to current therapies, ef-
fective and well-tolerated treatments are still lacking for both
low- and high-risk patients. Low-dose aspirin and phlebotomy
help manage the disease, but low-risk patients still have an
incidence of vascular events of 2.5 per 100 patients per year
(approximately double that of a normal control population)
[48]. In some patients, long-term treatment with phlebotomy
leads to patient noncompliance and clinical intolerance and
may result in iron deficiency, which very frequently leads to
fatigue and could potentially lead to reactive thrombocytosis
[49, 50]. Additionally, treatment with phlebotomy alone (vs
either 32P or chlorambucil plus phlebotomy) was associated
with a relatively high risk of thrombosis (23 %) in the Poly-
cythemia Vera Study Group 01 study [16, 49], although this
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as seen in the more recent CYTO-PV study [31]. Among
patients treated with HU, approximately one in four will de-
velop resistance (≈11 %) or intolerance (13 %) to this agent,
which eventually leads to an increased risk of death [13, 41].
Others who are treated with IFN are unable to continue treat-
ment due to the intolerable adverse effects associated with this
therapy [13, 24]; even 20 to 30 % of patients treated with
PEG-IFN develop IFN intolerance during long-term therapy
[45, 51].
Clinical experience indicates that a large proportion of pa-
tients (20–60 %) remain on HU therapy despite lack of re-
sponse and intolerance. HU resistance leads to an increased
risk of death and transformation to MF [41], highlighting the
importance of moving these patients to second-line therapies
or enrollment in clinical trials. Thus, a definition of HU
resistance/intolerance is essential. To this end, specific criteria
of HU intolerance/resistance in patients with PV have been
proposed by the ELN Working Group (Table 2) [52]. As mo-
lecularly targeted therapies become available for the manage-
ment of patients with MPN, it will become necessary to iden-
tify those who (a) will derive the most benefit and (b) are
resistant to or intolerant of existing treatment options.
New treatment options
With the development of several new therapies, including
targeted agents, standardized criteria for the interpretation
and comparison of clinical trials became imperative. In
2013, the ELN and the International Working Group-
Myeloproliferative Neoplasms Research and Treatment devel-
oped a set of response criteria to be used in clinical trials of
new agents (Table 3) [53]. The proposed criteria incorporate
clinical, hematologic, and histologic response assessments
and evaluate the long-term effects of new and experimental
drugs. These criteria are crucial for assessing therapeutic
outcomes in patients treated with novel agents and for the
approval process of these agents by regulatory agencies.
JAK2 inhibitors
The discovery of JAK2 V617F as the underlying mutation in
PV has led to the development of several molecularly targeted
therapies focusing on the inhibition of JAK2. The JAK2 in-
hibitors have demonstrated great activity in patients with MF.
Patients with PV who are resistant to or intolerant of HU or
IFN and/or are experiencing intractable pruritus, severe con-
stitutional symptoms, or marked splenomegaly might benefit
greatly from treatment with a JAK inhibitor, as opposed to
conventional therapy [37].
The first reported results of a JAK2 inhibitor for the treat-
ment of PV were those from the phase 2 study of lestaurtinib
in patients with PV/ET. Lestaurtinib has been shown to inhibit
proliferation and JAK2/STAT5 signaling in cells from patients
with myeloproliferative disorders (IC50=1 nM in vitro) in pre-
clinical studies [54]. The ability of lestaurtinib 80 mg twice
daily to decrease JAK2 V617F allele burden in patients with
PV (n=27) or ET (n=12) was examined in a phase 2, open-
label, multicenter study (NCT00586651) [55]. The primary
endpoint, a ≥15 % reduction in JAK2 V617F allele burden
in 15 % of patients, was not met. Lestaurtinib modestly re-
duced JAK2V617F allele burden and reduced spleen size in a
subset of patients. Every patient had ≥1 adverse event (AE),
most commonly gastrointestinal (95 %), 15 patients (38 %)
experienced serious AEs, and 23 (59%) withdrew due to AEs.
This study highlighted the need for further studies of JAK2
inhibition in the treatment of PV and/or the development of
other JAK2 inhibitors.
In 2011, ruxolitinib, a potent JAK1/JAK2 inhibitor, was
approved by the US Food and Drug Administration (FDA)
for the treatment of MF and later by the European Medicines
Agency for the treatment of splenomegaly and MF-related
Table 2 Definition of resistance to/intolerance of HU in patients with PV
After 3 months of ≥2 g/day of HU, any
one of the following:
OR At the lowest dose of HU required
to achieve a complete or partial
response, a any one of the following:
OR At any dose of HU





• Uncontrolled myeloproliferation (i.e., PLT
count >400×109/L and WBC
count >10×109/L)
• PLT count <100×109/L
• Failure to reduce massiveb splenomegaly
by >50 % by palpation or resolve
splenomegaly-related symptoms
• Hgb <100 g/L
From [53]
ANC absolute neutrophil count, Hct hematocrit, Hgb hemoglobin, HU hydroxyurea, PLT platelet, PV polycythemia vera, WBC white blood cell
a Complete response was defined as Hct <45 % without phlebotomy, platelet count ≤400×109 /L, WBC count ≤10×109 /L, and no disease-related
symptoms. Partial response was defined as Hct <45 % without phlebotomy or response in ≥3 other criteria
b Spleen extending >10 cm from the costal margin
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symptoms [56–58]. These approvals were based on the results
from two phase 3 Controlled Myelofibrosis Study with JAK
Inhibitor Therapy (COMFORT) studies [56–58] showing that
ruxolitinib was generally well tolerated and demonstrated rap-
id and durable clinical benefits, as well as a survival advan-
tage. Given ruxolitinib’s efficacy and safety profile in MF and
its activity as a JAK inhibitor, studies of its effects in patients
with PV have begun. In preclinical studies, ruxolitinib
inhibited erythroid colony formation from cells derived from
patients with PVas well as growth-factor-independent colony
formation, a unique characteristic of PVand other MPNs [59].
Results from a phase 2, open-label, dose-ranging study
(Incyte; N=34) suggested that ruxolitinib was well tolerated
and achieved rapid and durable clinical responses in patients
with PV who were resistant/intolerant to HU [60]. Response
was assessed using modified ELN criteria, which included a
reduction in Hct to <45 % without phlebotomy, resolution of
palpable splenomegaly, normalization of WBC and platelet
counts, and reduction in PV-associated symptoms. Response
was achieved in 97% of patients by week 24 (median duration
of exposure, 155 weeks) and was durable, with 85 %
maintaining response for 48 weeks. Ruxolitinib improved
PV-associated symptoms, including pruritus, night sweats,
and bone pain within 4 weeks of treatment initiation. Anemia
and thrombocytopenia (primarily grade 1) were the most com-
mon AEs.
Based on the promising results from the phase 2 dose-
ranging study, the first phase 3 trial of a JAK inhibitor
(ruxolitinib) in the treatment of PV, Randomized Study of
Efficacy and Safety in Polycythemia Vera with JAK Inhibitor
INCB018424 Versus Best Available Care (RESPONSE;
ClinicalTrials.gov identifier, NCT01243944), was initiated;
results were recently reported [61]. RESPONSE is an open-
label, randomized, phase 3 trial comparing the efficacy and
safety of ruxolitinib versus best available therapy (BAT) in
patients with PV who were resistant to or intolerant of HU
by modified ELN criteria. Patients were required to have
splenomegaly and need phlebotomy for adequate Hct control.
The primary endpoint was a composite of the percentage of
patients who achieved both Hct control (defined as the lower
of Hct <45 % that was ≤3 points lower than baseline or Hct
≤48 %) from week 8 to week 32 and a ≥35 % reduction in
Table 3 Response criteria for PV
Criteria
Complete remission
A Durablea resolution of disease-related signs including palpable
hepatosplenomegaly, large symptom improvement,b AND
B Durablea peripheral blood count remission, defined as Hct
<45 % without phlebotomy; platelet count ≤400×109/L,
WBC count <10×109/L, AND
C Without progressive disease and absence of any hemorrhagic
or thrombotic event, AND
D Bone marrow histologic remission defined as the presence
of age-adjusted normocellularity and
disappearance of trilinear hyperplasia and absence of
reticulin fibrosis > grade 1
Partial remission Achievement of A, B, and C without bone marrow
histologic remission defined as persistence of trilinear
hyperplasia
Molecular responsec
Complete response: eradication of a preexisting abnormality
Partial responsed: a ≥50 % decrease in allele burden
No response Any response that does not satisfy partial remission
Progressive disease Transformation into post-PV MF, MDS, or acute leukemia
Republished with permission of the American Society of Hematology, from Barosi G et al. [53]; permission
conveyed through Copyright Clearance Center, Inc.
Hct hematocrit, MDS myelodysplastic syndrome, MF myelofibrosis, PV polycythemia vera, WBC white blood
cell
a Lasting at least 12 weeks
b Large symptom improvement (≥10-point decrease) in the Myeloproliferative Neoplasm-Symptom Assessment
Form Total Symptom Score
cMolecular response is not required for assignment as complete response or partial response; it requires analysis
in peripheral blood granulocytes
d Partial response applies only to patients with at least 20 % mutant allele burden at baseline
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spleen volume from baseline at week 32. Overall, 21 % of
patients randomized to ruxolitinib (vs 1 % of BAT-treated
patients) achieved the primary endpoint (P<0.0001), with
77 % meeting at least one component. More patients in the
ruxolitinib arm had decreases from baseline in spleen volume
compared with those in the BAT arm (71.8 vs 33.0 %), with
38 % (vs 1 % in the BATarm) achieving a ≥35 % reduction in
spleen volume. Similarly, higher proportions of patients in the
ruxolitinib arm achievedHct control (60 vs 20%). In addition,
significantly more patients who received ruxolitinib achieved
complete hematologic remission (defined as Hct control,
platelets ≤400×109/L, and WBC count ≤10×109/L) at week
32 compared with those who received BAT (23.6 vs 8.9 %;
P=0.0034). Although it was not a predefined efficacy assess-
ment in the study, the rate of thromboembolic events was
lower in patients receiving ruxolitinib than in patients treated
with BAT (1 vs 6). Treatment with ruxolitinib also resulted in
great improvements in symptoms, as assessed by the MPN-
SAF questionnaire. Overall, ruxolitinib was generally well
tolerated and had a safety profile consistent with that seen in
the phase 3 COMFORT studies [56, 57], suggesting that
ruxolitinib may be a potential new treatment option for pa-
tients with PV who are classified as resistant to or intolerant of
HU according to modified ELN criteria.
Given that not all patients with PV present with
splenomegaly, ruxolitinib is also being evaluated in the
RESPONSE 2 trial [62]. RESPONSE 2 is a phase 3b,
open-label, randomized (1:1) study comparing the effica-
cy and safety of ruxolitinib with BAT in patients with
HU-resistant/intolerant PV who have a nonpalpable
spleen and thus were not eligible for the RESPONSE
trial. Another ongoing phase 3 study evaluating
ruxolitinib for the treatment of PV is the Randomized
Switch Study from Hydroxyurea to Ruxolitinib for
RELIEF of Polycythemia Vera Symptoms (RELIEF) trial
(Incyte; NCT01632904), a randomized (1:1), multicenter,
double-blind, double-dummy, phase 3 switch study eval-
uating the efficacy and safety of ruxolitinib vs HU for
the control of disease-related symptoms in patients with
PV currently reporting symptoms on HU monotherapy
[63]. The primary endpoint is the proportion of patients
with a ≥50 % reduction from baseline in symptoms in-
cluding tiredness, itching, muscle ache, night sweats, and
sweating while awake at week 16.
Momelotinib (CYT387), another JAK inhibitor cur-
rently under evaluation, is a JAK1/JAK2 inhibitor that
has demonstrated clinical improvement in MF in a phase
1/2 clinical study [64]. Treatment with momelotinib re-
sulted in a durable reduction of splenomegaly and the
achievement of sustained red blood cell transfusion inde-
pendence in a substantial number of participants in this
study. Based on these results, a phase 2, open-label, ran-
domized study evaluating the safety and efficacy of
momelotinib in patients with PV or ET is currently un-
derway (NCT01998828). Patients must be intolerant of,
resistant to, or refuse current available treatment for PV.
The primary endpoint is an overall response rate defined
as the proportion of participants who experience all of
the following for ≥4 weeks during the treatment period:
Hct <45 % in the absence of phlebotomy, WBC count
<10×109/L, platelet count ≤400×109/L, and resolution of
palpable splenomegaly.
One other JAK inhibitor still in early development is the
selective JAK2 inhibitor LY2784544, which has demonstrat-
ed dose-dependent selectivity for the mutated JAK2 V617F
over wild-type JAK2 [65]. LY2784544 was tested in a phase
1 study (NCT01134120) in 38 patients with JAK2 V617F-
positive MF (n=31), ET (n=1), or PV (n=6). The primary
objectives were to determine the safety and tolerability of
LY2784544 and to define a recommended dose for further
study. Of the six patients with PV, three achieved a
clinicohematologic partial response at a dose of 120 mg per
day. The most frequently reported drug-related AEs across all
grades were diarrhea (44 %); nausea (29 %); increased creat-
inine (21 %); and anemia, vomiting, and fatigue (9 % each);
there were no grade 4 AEs. The authors concluded that the
results support ongoing phase 2 testing at a daily dose of
120 mg.
Histone deacetylase inhibitors
Another class of targeted therapy being explored is histone
deacetylase (HDAC) inhibitors, which inhibit proliferation
of tumor cells by inducing cell cycle arrest, differentiation,
and/or apoptosis [66]. Givinostat has specificity for JAK2
V617F-mutated cells and has been tested in a pilot phase 2
study in patients with HU-resistant/intolerant JAK2 V617F-
positive PV (n=12) and ET (n=1) [67]. Givinostat was well
tolerated, with no grade 4 toxicities reported. Overall, 75 % of
patients had a reduction in splenomegaly and 54 % had a
clinical response after 12 weeks on treatment. Givinostat
was later evaluated in a multicenter, open-label phase 2 study
in patients with PV (n=44) who showed no response when
treated with the maximum tolerated doses of HU. Patients
were treated with givinostat (50 or 100 mg/day) in combina-
tion with HU at the maximum tolerated dose. The combina-
tion of givinostat and HU was well tolerated, and after
12 weeks of treatment, complete or partial response was ob-
served in 55 and 50 % of patients receiving 50 or 100 mg
givinostat, respectively. Improvements in pruritus were also
observed (64 and 67 %) [68].
Other HDAC inhibitors have not been as well tolerated.
Vorinostat was tested in a nonrandomized, open-label phase
2 trial enrolling patients with PV (n=44) and ET (n=19) [69].
Overall, 72 % of patients had a response, but 44 % of patients
discontinued treatment due to AEs.
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Pegylated interferon
Newer pegylated formulations of IFN (PEG-IFN), which are
better tolerated and allow for less frequent administration,
have renewed interest in IFN as a therapeutic option for pa-
tients with PV, including those who are refractory or resistant
to HU. In addition to having a more favorable toxicity profile
than HU and IFN, PEG-IFN treatment has been associated
with high rates of hematologic and molecular responses that
may prevent evolution toMF andAML.A 2008 phase 2 study
(N=37) found that all patients receiving PEG-IFN had a he-
matologic response and a reduction in JAK2 V617F allele
burden [45]. Similarly, another study (N=40) demonstrated
an overall hematologic response rate of 80 %, with a 14 %
complete molecular response [70]. However, PEG-IFN is con-
traindicated in patients with thyroid and psychiatric disorders,
and data on its prevention of thromboembolic events are lim-
ited. PEG-IFN is being tested in two phase 3 trials for the
treatment of PV. The first trial, sponsored by the Myeloprolif-
erative Disorder Research Consortium, is a randomized open-
label study evaluating the safety, tolerability, and efficacy of
PEG-IFN-2a (Pegasys) vs HU in patients with high-risk PVor
ET (NCT01259856) [71]. The primary outcome will be a
comparison of hematologic rates between the two study arms.
Pegylated Interferon Alpha-2b Versus Hydroxyurea in Poly-
cythemia Vera (PROUD-PV; NCT01949805), a second phase
3 study, is currently evaluating AOP2014, a novel PEG-IFN,
in patients with PV. This trial will compare the safety and
efficacy of AOP2014 with HU in patients who either have
not had prior exposure to HU or have had no response to prior
HU treatment [72]. The primary endpoint is the disease re-
sponse rate (Hct<45 % without phlebotomy, platelets
<400 g/L, leukocytes <10 g/L, and normal spleen size) at
12 months. This study is currently recruiting patients, with
an estimated enrollment of 256 patients.
Conclusions
PV is the most common of the MPNs. Patients experience
debilitating pruritus and fatigue and develop new symptoms,
such as splenomegaly, as the disease progresses, while facing
the risk ofmajor thrombotic events. Although PVis associated
with increased mortality, many patients have a long median
survival, highlighting the importance of effective and well-
tolerated therapy. Patients have limited therapeutic options,
and many must pursue inadequate treatment accompanied
by intolerable adverse effects and the risk of progression to
MF or hematologic transformation. The discovery of JAK2
mutations as the underlyingmolecular basis for PV has greatly
increased our understanding of the pathogenesis of PVand has
allowed for the development of targeted therapies. Already,
studies are assessing the clinical benefits of JAK2 inhibitors
and are showing promising results for the treatment of this
debilitating disease. Further studies will most likely focus on
which patients with PV will benefit most from the use of
targeted therapies and how these new therapies compare with
the current therapy standards. The best therapy for each pa-
tient will be one that is well tolerated while improving symp-
toms and quality of life, and in this regard, targeted therapies
will be valuable tools.
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